424 related articles for article (PubMed ID: 33205034)
1. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors.
De Martin E; Michot JM; Rosmorduc O; Guettier C; Samuel D
JHEP Rep; 2020 Dec; 2(6):100170. PubMed ID: 33205034
[TBL] [Abstract][Full Text] [Related]
2. Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors.
Parlati L; Sakka M; Retbi A; Bouam S; Hassani L; Meritet JF; Rufat P; Bonnefont-Rousselot D; Batista R; Terris B; Bellanger A; Thabut D; Vozy A; Spano JP; Coriat R; Goldwasser F; Aractingi S; Sogni P; Pol S; Mallet V; ;
JHEP Rep; 2023 Dec; 5(12):100880. PubMed ID: 38074948
[TBL] [Abstract][Full Text] [Related]
3. Approach to the patient with acute severe autoimmune hepatitis.
Rahim MN; Miquel R; Heneghan MA
JHEP Rep; 2020 Dec; 2(6):100149. PubMed ID: 32995712
[TBL] [Abstract][Full Text] [Related]
4. The ABC of Immune-Mediated Hepatitis during Immunotherapy in Patients with Cancer: From Pathogenesis to Multidisciplinary Management.
Lasagna A; Sacchi P
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398187
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors.
Chen KY; Popovic A; Hsiehchen D; Baretti M; Griffith P; Bista R; Baghdadi A; Kamel IR; Simon SM; Migler RD; Yarchoan M
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358766
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of immune checkpoint inhibitor-induced liver toxicity managed by hepatologists in a multidisciplinary toxicity team.
Ito T; Mizuno K; Yamamoto T; Yasuda T; Yokoyama S; Yamamoto K; Imai N; Ishizu Y; Honda T; Hama M; Kataoka T; Shimokata T; Ando Y; Kawashima H
Hepatol Res; 2024 Apr; ():. PubMed ID: 38571477
[TBL] [Abstract][Full Text] [Related]
7. Risk Factors for Immune Checkpoint Inhibitor-Induced Liver Injury and the Significance of Liver Biopsy.
Kawano M; Yano Y; Yamamoto A; Yasutomi E; Inoue Y; Kitadai J; Yoshida R; Matsuura T; Shiomi Y; Ueda Y; Kodama Y
Diagnostics (Basel); 2024 Apr; 14(8):. PubMed ID: 38667461
[TBL] [Abstract][Full Text] [Related]
8. Overlapping Hepatotoxicity and Colitis Associated with Immune Checkpoint Inhibitors.
Malik A; Yousaf MN; Samiullah S; Tahan V; Mahdi A
J Community Hosp Intern Med Perspect; 2023; 13(3):75-78. PubMed ID: 37877043
[TBL] [Abstract][Full Text] [Related]
9. Erlotinib-induced Hepatotoxicity-Clinical Presentation and Successful Management: A Case Report.
Arora AK
J Clin Exp Hepatol; 2011 Jun; 1(1):38-40. PubMed ID: 25755309
[TBL] [Abstract][Full Text] [Related]
10. Tolerated Re-Challenge of Immunotherapy in a Patient with ICI Associated Myocarditis: A Case Report and Literature Review.
Shalata W; Attal ZG; Shhadi R; Abu Salman A; Abu Jama A; Shalata S; Halumi K; Yakobson A
Medicina (Kaunas); 2023 Nov; 59(11):. PubMed ID: 38003995
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of High-Grade Immune Checkpoint Inhibitor Hepatitis in Hospitalized and Nonhospitalized Patients.
Li M; Wong D; Sack JS; Vogel AS; Hodi FS; Fong L; Lai JC; Zucker SD; Grover S
Clin Gastroenterol Hepatol; 2024 Jul; 22(7):1444-1452.e4. PubMed ID: 38401693
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma and Their Hepatic-Related Side Effects: A Review.
Ruli TM; Pollack ED; Lodh A; Evers CD; Price CA; Shoreibah M
Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893164
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of immune checkpoint inhibitor-mediated liver injury.
Shojaie L; Ali M; Iorga A; Dara L
Acta Pharm Sin B; 2021 Dec; 11(12):3727-3739. PubMed ID: 35024302
[TBL] [Abstract][Full Text] [Related]
14. Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors.
Sisi M; Vitale G; Fusaroli M; Riefolo M; Giunchi V; D'Errico A; Ardizzoni A; Raschi E; Gelsomino F
JTO Clin Res Rep; 2023 Sep; 4(9):100563. PubMed ID: 37745898
[TBL] [Abstract][Full Text] [Related]
15. Predictive Biomarkers of Immune Checkpoint Inhibitor-Based Mono- and Combination Therapies for Hepatocellular Carcinoma.
Jeng LB; Wang J; Teng CF
J Cancer; 2024; 15(2):484-493. PubMed ID: 38169551
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade.
Reynolds K; Thomas M; Dougan M
Oncologist; 2018 Sep; 23(9):991-997. PubMed ID: 29853659
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of immunotherapy-related hepatotoxicity from a multi-disciplinary toxicity team.
Fan C; Kim A; Li S; Naidoo J; Cappelli LC; Brahmer JR; Anders RA; Kim AK
J Cancer Res Clin Oncol; 2023 Feb; 149(2):877-883. PubMed ID: 36102989
[TBL] [Abstract][Full Text] [Related]
18. New strategies in the diagnosis and treatment of immune-checkpoint inhibitor-mediated colitis.
Velikova T; Krastev B; Gulinac M; Zashev M; Graklanov V; Peruhova M
World J Clin Cases; 2024 Feb; 12(6):1050-1062. PubMed ID: 38464930
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology.
Alouani E; Laparra A; Perret A; Sakkal M; Messayke S; Danlos FX; Ouali K; Hollebecque A; Even C; Ammari S; Baldini C; Champiat S; Besse B; Robert C; Guettier C; Samuel D; Lambotte O; De Martin E; Michot JM
Eur J Cancer; 2023 Nov; 193():113313. PubMed ID: 37748398
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic guide for immune checkpoint inhibitor-induced liver injury.
Ito T; Takeuchi Y; Mizuno K; Imai M; Yoshimaru Y; Abe K; Abe M; Matsuura T; Yokode M; Shiokawa M; Kodama Y; Komuta M; Harada K; Tanaka A
Hepatol Res; 2024 Jun; ():. PubMed ID: 38884591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
